Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Raccolta di campioni di sangue per nuovi dispositivi diagnostici 2 (NOVEL-2)

12 novembre 2026 aggiornato da: LumiraDx UK Limited

Raccolta di campioni di sangue venoso e capillare per la ricerca, l'ottimizzazione e la calibrazione di nuovi dispositivi diagnostici 2

To research and develop new state of the art diagnostic biomarkers on the LumiraDx Platform that are comparable to the approved gold standard reference methods and will radically enhance clinicians and patients ability to monitor health conditions and improve outcomes by delivering the results near patient at the point of care.

Panoramica dello studio

Descrizione dettagliata

This is a comparative research study to research, optimise and develop new state of the art diagnostic biomarkers on the LumiraDx Platform that will radically enhance clinicians and patients ability to monitor chronic health conditions which improve outcomes at the point of care and that are comparable to gold standard reference methods. The LumiraDx POC Platform consists of an in vitro diagnostic instrument, used with single use test strips for different disease biomarkers. This next generation point of care device is intended to allow multiple tests to be performed on the same platform for blood, plasma, serum, swab, and urine samples.

Research activities will be completed on blood samples collected from a maximum of 20,000 patients to assess the performance of the new biomarkers undergoing research. Patients will include those presenting at a medical unit (including but not limited to A&E departments, hospital wards, or out-patient clinics) to their care team, in order to obtain a range of values for research of the new biomarkers on the LumiraDx system. Participants will include those who are expected to have (but are not limited to) biomarkers for diseases areas including embolism, infection or inflammation, cardiovascular, and renal cohorts.

Each patient must give appropriate written informed consent and satisfy all the inclusion/exclusion criteria prior to any study procedures. Patient participation in this study will take a maximum of 45 minutes of the patient's time. Patients presenting for a subsequent clinic visit or admission may be approached to participate in the study again, a maximum of 24mL of venous whole blood and up to 6 capillary fingersticks (obtained with a high flow lancet) may be collected from each patient within a three month period. Where possible, study samples should be taken at the same time as any standard of care blood draws or from patients with a cannula in-situ, a separate study venipuncture is not a requirement for this protocol. Study samples will be used for research, evaluation, optimisation and development activities into new biomarkers on the LumiraDx Platform in comparison with the gold standard reference method for the disease area to ensure comparable performance. Samples may also be used for troubleshooting and calibrating LumiraDx assays developed.

Sample collection will be separated into 2 phases depending upon the research needs. Patients can participate in both phases:

Phase 1: Only venous blood samples will be drawn by the HCP. These samples will be tested on the LumiraDx System and/or device(s) under development and also tested on the appropriate reference method for comparison. This testing may occur at the clinical site and/or at LumiraDx UK Ltd.

Phase 2: Venous blood samples and capillary fingerstick samples will be collected by the HCP. These samples may be tested on the LumiraDx Platform and also tested on the appropriate reference method for comparison. The fingerstick samples will be tested on the LumiraDx device. The processing of samples may occur at the clinical site and/or at LumiraDX UK Ltd.

The samples will be identified by patient identification number, anonymising the patient's identifiable information. These blood samples will be sent to LumiraDx UK Ltd for storage and future testing. No genetic testing will be carried out on samples. Samples may also be used to research, optimise, develop, modify and calibrate products and platforms for measuring biomarkers including, but not limited to, Troponin, NT-pro BNP, BNP, CK-MB, D-Dimer, NGAL, Cystatin C, Myoglobin, Galectin-3, CRP, AST, ALT, Lipids, Coagulation, Prolactin, and Beta-hCG.

Patients who reattend or are admitted to the medical unit (including but not limited to A&E departments, hospital wards or out-patient clinics) may be asked for further sampling. A total of 24mL and 6 capillary fingersticks (obtained using high flow lancets) will not be exceeded over the three month period from consent, patients may opt out of further contact. Any patient reattending three months post consent will be treated as a new patient.

Data will be recorded on the Case Report Forms. The patient demographics data collected may include: age; sex; ethnicity, pregnancy status, NYHA classification, current medications at time of blood collection including their indications, significant medical history, relevant local blood test results, reason(s) for presenting, and confirmed diagnosis.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

16063

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Scotland
      • Airdrie, Scotland, Regno Unito, ML6 0JS
        • University Hospital Monklands
      • Edinburgh, Scotland, Regno Unito, EH16 4SA
        • Royal Infirmary of Edinburgh
      • Edinburgh, Scotland, Regno Unito, EH54 6PP
        • St John's Hospital
      • Glasgow, Scotland, Regno Unito, G51 4TF
        • Queen Elizabeth University Hospital
      • Glasgow, Scotland, Regno Unito, G4 0SF
        • Glasgow Royal Infirmary
      • Glasgow, Scotland, Regno Unito, G81 4DY
        • Golden Jubilee National Hospital
      • Paisley, Scotland, Regno Unito, PA2 9PN
        • Royal Alexandra Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Patients will include those presenting at a medical unit (including but not limited to A&E departments, hospital wards, or out-patient clinics) to their care team, in order to obtain a range of values for research of the new biomarkers on the LumiraDx system. Participants will include those who are expected to have (but are not limited to) biomarkers for diseases areas including embolism, infection or inflammation, cardiovascular, and renal cohorts.

Descrizione

Inclusion Criteria

  • Subject 18 years of age.

  • Willing and able to provide written informed consent and comply with study procedures.

  • Patients attending a definitive care team with research capabilities which has been enroled in this collection study.

  • Patients who can read and understand written English.

  • The subject must present as one of the following cohorts:

    1. Group A - Embolism Cohort - Patients presenting with symptoms indicative of thromboembolic events.
    2. Group B - Infection or Inflammation Cohort - Patients presenting with symptoms indicative of infection or inflammatory disorders.
    3. Group C - Cardiovascular Cohort - Patients presenting with symptoms indicative of heart failure or acute coronary syndrome.
    4. Group D - Renal Cohort - Patients presenting with symptoms indicative of renal disorders.
    5. Group E - Other Cohort. - Patients who are not eligible for any of the above groups.

Exclusion Criteria

  • Subject <18 years of age.
  • Vulnerable populations deemed inappropriate for the study by the sites Principal Investigator.
  • Patients who have previously been enroled in any LumiraDx NOVEL study in the past 3 months and re-entry would breach the 24mL and or 6 fingersitck maximums.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Blood Draw

Venous blood draw up to 24mL and/or 6 capillary fingersticks

Interventions:

Diagnostic Test: Venepuncture Diagnostic Test: Fingerstick

Venepuncture to draw up to 24mL of venous blood.

Capillary blood draw

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Measurement of blood samples from patients with infection, cardiovascular disease, embolism or renal disease in a reference method and in a novel LumiraDx method.
Lasso di tempo: Up to 5 years

Measurement of blood samples in a reference method and in a novel LumiraDx method to assess accuracy of the LumiraDx method in patients with infection, cardiovascular disease, embolism or renal disease. Accuracy will be assessed by regression analysis against a reference method.

Up to 5 years
Multiple measurements of blood samples from patients with infection, cardiovascular disease, embolism or renal disease in a novel LumiraDx method.
Lasso di tempo: Up to 5 years

Multiple measurements of blood samples in a novel LumiraDx method to assess precision of the method in patients with infection, cardiovascular disease, embolism or renal disease. Precision will be assessed by coefficient of variation (%CV) estimates.

Up to 5 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Roy Gardner, NHS National Waiting Times Centre Board
  • Investigatore principale: Alasdair Gray, NHS Lothian
  • Investigatore principale: Fiona Hunter, NHS Lanarkshire
  • Investigatore principale: Allan Cameron, NHS Greater Glasgow and Clyde
  • Investigatore principale: David Lowe, NHS Greater Glasgow and Clyde
  • Investigatore principale: Santosh Bongale, NHS Greater Glasgow and Clyde

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

11 luglio 2022

Completamento primario (Effettivo)

17 settembre 2026

Completamento dello studio (Effettivo)

17 settembre 2026

Date di iscrizione allo studio

Primo inviato

21 settembre 2022

Primo inviato che soddisfa i criteri di controllo qualità

3 ottobre 2022

Primo Inserito (Effettivo)

6 ottobre 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi